1. Risk factors and prognosis of early death in secondary hemophagocytic lymphohistiocytosis

   • Qiaolei Zhang
   • Lixia Zhu
   • Xiujin Ye

   Original Article 02 June 2023 Pages: 2301 - 2308

   

2. Are accessory spleen screening and resection in refractory immune cytopenia an effective strategy or a waste of resources?

   • Sergio Rodríguez-Rodríguez
   • José Miguel Álvarez-Blanco
   • Roberta Demichelis-Gómez

   Original Article 13 July 2023 Pages: 2309 - 2315

   

3. The mTORC1 pathway participate in hyper-function of B cells in immune thrombocytopenia

   • Yujiao Xiang
   • Lu Liu
   • Yan Shi

   Original Article 08 July 2023 Pages: 2317 - 2327

   

4. Age-related differences in risks and outcomes of 30-day readmission in adults with sickle cell disease

   • Ming Chen
   • Kenneth I. Ataga
   • James E. Bailey

   Original Article 14 July 2023 Pages: 2329 - 2342

   

5. Molecular insights into hereditary elliptocytosis and pyropoikilocytosis: NGS uncovers multiple potential candidate genes

   • Durjoy K. Shome
   • Priya Das
   • Rehab Helmy

   Original Article 04 July 2023 Pages: 2343 - 2351

   

6. Insulin-like growth factor 1 receptor inhibits the proliferation of acute myeloid leukaemia cells via NK cell activation

   • ShuQing Wang
   • Xuan Wang
   • Jian Li

   Original Article 31 July 2023 Pages: 2353 - 2364

   

7. Platelet is an unfavorable prognostic biomarker and associated with leukemia stem cells and immunomodulatory factors in acute myeloid leukemia

   • Qing Zhang
   • Haotian Yan
   • Zhimin Zhai

   Original Article 15 July 2023 Pages: 2365 - 2373

   

8. Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years

   • Dongdong Niu
   • Yumei Zhao
   • Jiayuan Wu

   Original Article 19 July 2023 Pages: 2375 - 2386

   

9. Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis

   • Chunxiao Liu
   • Xuewu Zhang
   • Wenjuan Yu

   Original Article 06 June 2023 Pages: 2387 - 2395

   

10. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review

    • Kai-Wen Tan
    • Yi-Yan Zhu
    • Sheng-Li Xue

    Original Article 27 April 2023 Pages: 2397 - 2402

    

11. Positron emission tomography to detect bone marrow involvement for patients with follicular lymphoma: a systematic review and meta-analysis

    • Yaxin Zheng
    • Jun Liu
    • Chen Tian

    Original Article 20 May 2023 Pages: 2403 - 2412

    

12. MYC-targeted genes predict distant recurrence in patients with ocular adnexal extranodal marginal zone lymphoma

    • Tianyu Zhu
    • Jiahao Shi
    • Yixiong Zhou

    Original Article 21 April 2023 Pages: 2413 - 2423

    

13. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis

    • Yangyang Ding
    • Cheng Sun
    • Zhimin Zhai

    Original Article 29 June 2023 Pages: 2425 - 2434

    

14. Clinical significance of plasma PD-L1⁺ exosomes in the management of diffuse large B cell lymphoma

    • Peng Xu
    • Juan Liu
    • Yan Lin

    Original Article 10 May 2023 Pages: 2435 - 2444

    

15. Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series

    • Mengze Hu
    • Rong Liu
    • Ruihong Tang

    Original Article 20 May 2023 Pages: 2445 - 2457

16. Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study

    • Jia-Ying Li
    • Xiao-Rong Hou
    • Ye-Xiong Li

    Original Article Open access 12 June 2023 Pages: 2459 - 2469

    

17. Dynamic changes in circulating EBV-DNA load during treatment have prognostic values in EBV⁺ DLBCL-NOS: a Chinese cohort study

    • Tong-Yao Xing
    • Zi-Wen Duan
    • Wei Xu

    Original Article 10 May 2023 Pages: 2471 - 2481

    

18. ADAR1 polymorphisms contribute to increased susceptibility in pediatric acute lymphoblastic leukemia

    • Mansi Cai
    • Xiaoping Liu
    • Xiaodan Liu

    Original Article 22 May 2023 Pages: 2483 - 2492

    

19. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma

    • Yu Abe
    • Makoto Sasaki
    • Kenshi Suzuki

    Original Article Open access 21 June 2023 Pages: 2493 - 2504

    

20. Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma

    • Yu Abe
    • Makoto Sasaki
    • Kenshi Suzuki

    Correction Open access 11 July 2023 Pages: 2505 - 2505

21. Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group

    • Masuho Saburi
    • Kumi Oshima
    • Transplant Complications Working Group of the Japanese Society for Transplantation and Cellular Therapy

    Original Article 20 June 2023 Pages: 2507 - 2516

    

22. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction

    • Vivian W.K. Li
    • Rita Yim
    • Harinder Gill

    Original Article 17 June 2023 Pages: 2517 - 2527

    

23. The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease

    • Michael Stadler
    • Lothar Hambach
    • Arnold Ganser

    Original Article Open access 25 July 2023 Pages: 2529 - 2542

    

24. Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)

    • Alexander Pohlmann
    • Eva Bentgens
    • Christoph Schliemann

    Original Article Open access 10 July 2023 Pages: 2543 - 2553

    

25. Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era — real-world data from Hungary

    • Kata Husi
    • Roxána Szabó
    • Zsófia Miltényi

    Original Article Open access 10 July 2023 Pages: 2555 - 2563

    

26. Meta-analysis of the results of haploidentical transplantation in the treatment of aplastic anemia

    • Jin Zhao
    • Li Ma
    • Xiaojing Guo

    Original Article 13 July 2023 Pages: 2565 - 2587

    

27. Time-dependent analysis of the impact on early cytomegalovirus reactivation of HLA mismatch and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation from related donors in acquired aplastic anemia

    • Fan Lin
    • Xinyu Dong
    • Lanping Xu

    Original Article 13 July 2023 Pages: 2589 - 2598

    

28. Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients

    • A. Chistolini
    • A. Serrao
    • C. Santoro

    Original Article 21 July 2023 Pages: 2599 - 2605

    

29. Tigecycline as salvage treatment of febrile neutropenia in patients with haematological malignancies—a retrospective single-centre analysis of 200 cases

    • Daniel Geßner
    • Mirjeta Berisha
    • Enrico Schalk

    Original Article Open access 25 April 2023 Pages: 2607 - 2616

    

30. Heyde syndrome

    • Edwin Uriel Suárez
    • Rosa Vidal-Laso

    Letter to the Editor 29 May 2023 Pages: 2617 - 2618

    

31. Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response

    • Gerasimos Tsilimidos
    • Sabine Blum

    Letter to the Editor 31 May 2023 Pages: 2619 - 2620

32. Mast cell leukemia associated with essential thrombocythemia: a type of MCL-AHN (MCL-AMN)

    • Magda Zanelli
    • Francesca Sanguedolce
    • Stefano Ascani

    Letter to the Editor 08 June 2023 Pages: 2621 - 2623

    

33. Paroxysmal nocturnal hemoglobinuria with ulcerative colitis

    • Kenta Hayashino
    • Yuki Fujiwara
    • Yasushi Hiramatsu

    Letter to the Editor 20 June 2023 Pages: 2625 - 2626

    

34. The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

    • Zhiyou Yu
    • Yao Yao
    • Ying Wang

    Letter to the Editor 10 June 2023 Pages: 2627 - 2630

    

35. Characteristics and outcomes associated with venous thrombotic complications among patients with paroxysmal nocturnal hemoglobinuria

    • Udhayvir S. Grewal
    • Sahith R. Thotamgari
    • Usha Perepu

    Letter to the Editor 22 June 2023 Pages: 2631 - 2632

36. Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome

    • Katarina Tomulic Brusich
    • Kazimir Juricic
    • Ana Boban

    Letter to the Editor 26 June 2023 Pages: 2633 - 2634

37. COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma

    • Victoria R. Nachar
    • Anthony J. Perissinotti
    • Tycel J. Phillips

    Letter to the Editor 09 June 2023 Pages: 2635 - 2637

38. Cyclin D2-positive mantle cell lymphoma with t(2;12)(p12;p13) arising in immune deficiency/dysregulation

    • Takumi Kondo
    • Mitsuko Iguchi
    • Kensuke Kojima

    Letter to the Editor 23 June 2023 Pages: 2639 - 2640

    

39. Erythema nodosum as a manifestation of cytokine release syndrome after CAR T-cell therapy

    • Delfim Duarte
    • José Mário Mariz

    Letter to the Editor 24 June 2023 Pages: 2641 - 2642

    

40. Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

    • Grzegorz S. Nowakowski
    • Dok Hyun Yoon
    • Gilles Salles

    Correction Open access 11 July 2023 Pages: 2643 - 2644